| 2024 | 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association
| DIABETES & METABOLISM JOURNAL |
| 2024 | Appendicular Skeletal Muscle Mass to Visceral Fat Area Ratio Predicts Hepatic Morbidities
| GUT AND LIVER |
| 2024 | Dysregulation of autophagy activation induced by atorvastatin contributes to new-onset diabetes mellitus in western diet-fed mice | METABOLISM-CLINICAL AND EXPERIMENTAL |
| 2024 | Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study | METABOLISM-CLINICAL AND EXPERIMENTAL |
| 2024 | Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes
| DIABETES THERAPY |
| 2024 | Intact ketogenesis predicted reduced risk of moderate-severe metabolic-associated fatty liver disease assessed by liver transient elastography in newly diagnosed type 2 diabetes
| FRONTIERS IN ENDOCRINOLOGY |
| 2023 | Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial
| DIABETES & METABOLISM JOURNAL |
| 2023 | Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis | AMERICAN JOURNAL OF NEPHROLOGY |
| 2023 | Safety and Clinical Outcomes of Insulin Degludec in Korean Patients with Diabetes in Real-World Practices: A Prospective, Observational Study
| DIABETES THERAPY |
| 2023 | Association between Impaired Ketogenesis and Metabolic-Associated Fatty Liver Disease
| BIOMOLECULES |
| 2023 | Glucometabolic control of once-weekly dulaglutide switched from DPP4 inhibitor versus daily empagliflozin add-on in patients with type 2 diabetes inadequately controlled with metformin, sulfonylurea, and DPP4 inhibitor: A randomised trial | DIABETES RESEARCH AND CLINICAL PRACTICE |
| 2023 | MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2023 | Significance of Diabetic Kidney Disease Biomarkers in Predicting Metabolic-Associated Fatty Liver Disease
| BIOMEDICINES |
| 2023 | β-hydroxybutyrate as a biomarker of β-cell function in new-onset type 2 diabetes and its association with treatment response at 8 months | DIABETES & METABOLISM |
| 2023 | Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial | NATURE MEDICINE |
| 2023 | Highly selective electrochemical quantitation of creatinine based on its chemical reaction with 3,5-dinitrobenzoate | JOURNAL OF ELECTROANALYTICAL CHEMISTRY |
| 2023 | Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION)
| Endocrinology and Metabolism(대한내분비학회지) |
| 2023 | Age at Mortality in Patients with Type 2 Diabetes Who Underwent Kidney Transplantation: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
| JOURNAL OF CLINICAL MEDICINE |
| 2023 | Impaired ketogenesis is associated with metabolic-associated fatty liver disease in subjects with type 2 diabetes
| FRONTIERS IN ENDOCRINOLOGY |
| 2022 | Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease
| DIABETES & METABOLISM JOURNAL |
| 2022 | Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease
| GUT AND LIVER |
| 2022 | The effects of the voglibose on non-alcoholic fatty liver disease in mice model
| SCIENTIFIC REPORTS |
| 2022 | Protective Effect of Delta-Like 1 Homolog Against Muscular Atrophy in a Mouse Model
| Endocrinology and Metabolism(대한내분비학회지) |
| 2022 | Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
| FRONTIERS IN ENDOCRINOLOGY |
| 2022 | Improvement in Age at Mortality and Changes in Causes of Death in the Population with Diabetes: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
| Endocrinology and Metabolism(대한내분비학회지) |
| 2022 | Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double-blind, and placebo-controlled study | DIABETES OBESITY & METABOLISM |
| 2022 | Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease | HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL |
| 2022 | Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
| YONSEI MEDICAL JOURNAL |
| 2022 | SOLUTION study: Effect of gemigliptin as add-on therapy to dapagliflozin plus metformin in patients with type 2 diabetes | DIABETES RESEARCH AND CLINICAL PRACTICE |
| 2022 | Short Term Isocaloric Ketogenic Diet Modulates NLRP3 Inflammasome Via B-hydroxybutyrate and Fibroblast Growth Factor 21
| FRONTIERS IN IMMUNOLOGY |
| 2022 | Severe Hypoglycemia Increases Dementia Risk and Related Mortality: A Nationwide, Population-based Cohort Study | JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM |
| 2022 | Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial | DIABETES OBESITY & METABOLISM |
| 2022 | Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)
| BMC MEDICINE |
| 2022 | Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease
| GUT AND LIVER |
| 2022 | Analysis of Severe Hypoglycemia Among Adults With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
| JAMA NETWORK OPEN |
| 2022 | Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus
| DIABETES & METABOLISM JOURNAL |
| 2021 | Uric Acid Variability as a Predictive Marker of Newly Developed Cardiovascular Events in Type 2 Diabetes
| FRONTIERS IN CARDIOVASCULAR MEDICINE |
| 2021 | Proteinuria as a significant predictive factor for the progression of carotid artery atherosclerosis in non-albuminuric type 2 diabetes | DIABETES RESEARCH AND CLINICAL PRACTICE |
| 2021 | Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway
| DIABETES & METABOLISM JOURNAL |
| 2021 | 2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
| DIABETES & METABOLISM JOURNAL |
| 2021 | Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study
| DIABETES & METABOLISM JOURNAL |
| 2021 | Nonalcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetes | DIABETES OBESITY & METABOLISM |
| 2021 | Non-Albumin Proteinuria (NAP) as a Complementary Marker for Diabetic Kidney Disease (DKD)
| LIFE-BASEL |
| 2021 | Glycaemic control with add-on thiazolidinedione or a sodium-glucose co-transporter-2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24-week, randomized controlled trial | DIABETES OBESITY & METABOLISM |
| 2021 | Age at Diagnosis and the Risk of Diabetic Nephropathy in Young Patients with Type 1 Diabetes Mellitus
| DIABETES & METABOLISM JOURNAL |
| 2020 | Clinical Outcomes of COVID-19 Patients with Type 2 Diabetes: A Population-Based Study in Korea
| Endocrinology and Metabolism(대한내분비학회지) |
| 2020 | Metformin and Gastrointestinal Cancer Development in Newly Diagnosed Type 2 Diabetes: A Population-Based Study in Korea
| CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY |
| 2020 | Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
| DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY |
| 2020 | Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial
| CLINICAL THERAPEUTICS |
| 2020 | Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression
| SCIENTIFIC REPORTS |
http://orcid.org/0000-0002-9899-4992
(15763315600)
